Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7922827 | 1.00 | FBP1 (0.49) | FBP1NPC1RAB9ACYP1A2PTGS1 | |
| SCHEMBL7926738 | 0.80 | ALDH1A1 (0.48) | FBP1NPC1PTGS1TDP1PTGS2 | |
| SCHEMBL15216500 | 0.80 | ALDH1A1 (0.48) | FBP1NPC1PTGS1TDP1PTGS2 | |
| SCHEMBL15216486 | 0.79 | FBP1 (0.54) | FBP1TSHR | |
| SCHEMBL15216491 | 0.78 | FBP1 (0.44) | FBP1NPC1RAB9APTGS1TDP1 | |
| SCHEMBL28552488 | 0.78 | FBP1 (0.44) | FBP1NPC1RAB9APTGS1TDP1 | |
| SCHEMBL7921065 | 0.77 | ALDH1A1 (0.40) | CYP1A2TDP1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL4712004 | 0.76 | TDP1 (0.43) | FBP1TDP1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL6935466 | 0.76 | GAA (0.55) | NPC1RAB9ACYP1A2TDP1ALDH1A1 | |
| SCHEMBL729012 | 0.76 | TDP1 (0.40) | TDP1ALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225694-A1 | COMPOSITIONS AND METHODS OF INHIBITING RETINAL DEGENERATION | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225694-A1 | COMPOSITIONS AND METHODS OF INHIBITING RETINAL DEGENERATION | ALDH1A2, PDE6C, NQO1 | FBP1 668/4885NPC1 731/4885RAB9A 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.